- Home
- WKSP vs CVKD Comparison
WKSP vs CVKD Comparison
Compare WKSP & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WKSP
- CVKD
- Stock Information
- Founded
- WKSP 2003
- CVKD 2022
- Country
- WKSP United States
- CVKD United States
- Employees
- WKSP N/A
- CVKD N/A
- Industry
- WKSP Auto Parts:O.E.M.
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- WKSP Consumer Discretionary
- CVKD Health Care
- Exchange
- WKSP Nasdaq
- CVKD Nasdaq
- Market Cap
- WKSP 29.6M
- CVKD 34.2M
- IPO Year
- WKSP N/A
- CVKD 2023
- Fundamental
- Price
- WKSP $0.79
- CVKD $19.89
- Analyst Decision
- WKSP Strong Buy
- CVKD Strong Buy
- Analyst Count
- WKSP 2
- CVKD 1
- Target Price
- WKSP $1.75
- CVKD $32.00
- AVG Volume (30 Days)
- WKSP 943.8K
- CVKD 36.6K
- Earning Date
- WKSP 03-27-2025
- CVKD 03-10-2025
- Dividend Yield
- WKSP N/A
- CVKD N/A
- EPS Growth
- WKSP N/A
- CVKD N/A
- EPS
- WKSP N/A
- CVKD N/A
- Revenue
- WKSP $6,395,908.00
- CVKD N/A
- Revenue This Year
- WKSP $432.42
- CVKD N/A
- Revenue Next Year
- WKSP $239.28
- CVKD N/A
- P/E Ratio
- WKSP N/A
- CVKD N/A
- Revenue Growth
- WKSP 776.97
- CVKD N/A
- 52 Week Low
- WKSP $0.36
- CVKD $5.40
- 52 Week High
- WKSP $1.33
- CVKD $20.79
- Technical
- Relative Strength Index (RSI)
- WKSP 38.35
- CVKD 59.16
- Support Level
- WKSP $0.88
- CVKD $18.87
- Resistance Level
- WKSP $0.85
- CVKD $20.26
- Average True Range (ATR)
- WKSP 0.05
- CVKD 1.19
- MACD
- WKSP -0.02
- CVKD -0.08
- Stochastic Oscillator
- WKSP 9.59
- CVKD 82.52
About WKSP Worksport Ltd.
Worksport Ltd through its subsidiaries, designs, develops, manufactures, and owns the IP on a variety of tonneau covers, solar integrations, and NP (Non-Parasitic), Hydrogen-based true green energy solutions for the sustainable, clean energy, and automotive industries. The company's product includes soft vinyl tonneau covers and hard aluminum tonneau covers.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.